Nomic Bio partnered with Broad Clinical Labs (BCL) to integrate Nomic’s Nomic Omni 1000 immunoassay platform into BCL’s omics offerings. The collaboration is intended to incorporate quantitative proteomics into genomic disease-risk models and precision oncology workflows, including clinical trials and population-scale multiomic studies, with joint applications planned for early 2027.